U.S., Oct. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07884708) titled 'Chidamide, Lenalidomide, and Rituximab in Newly Diagnosed Elderly/unFit DE-DLBCL' on June 23, 2025.
Brief Summary: To evaluate the efficacy and safety of Chidamide in combination with lenalidomide and rituximab (CR2) as induction therapy, followed by chidamide maintenance in responding patients with newly diagnosed elderly/unfit double-expressor DLBCL.
Study Start Date: March 11, 2024
Study Type: INTERVENTIONAL
Condition:
Double Expressor DLBCL
ELDERLY PEOPLE
Unfit, New-diagnosis DLBCL
Intervention:
DRUG: Chidamide in combination with Lenalidomide and Rituximab (CR2)
The treatment consists of induction therapy followed by mai...